市場調査レポート

商品コード

1561040

がんバイオマーカーの市場規模、シェア、成長分析、プロファイリング技術別、がんタイプ別、製品別、用途別、地域別 - 産業予測、2024年～2031年

Cancer Biomarkers Market Size, Share, Growth Analysis, By Profiling Technology, By Cancer Type, By Product, By Application, By Region - Industry Forecast 2024-2031

出版日: 2024年09月16日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 763,518円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 893,172円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,022,826円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.06円

全表示
概要
目次

概要

サンプル依頼リストに入れる

がんバイオマーカーの世界市場規模は、2022年に238億米ドルと評価され、2023年の264億7,000万米ドルから2031年には618億8,000万米ドルに成長し、予測期間中（2024-2031年）のCAGRは11.8％で成長する見通しです。

世界のがんバイオマーカー市場の成長予測は、乳がん、前立腺がん、肺がんなど、さまざまながんの有病率の上昇と密接に結びついています。これらのがんの罹患率の増加は、今後数年間の市場拡大を促進する重要な要因です。さらに、がん治療における生物学的標的治療の重要性の高まりが、効果的なバイオマーカーの需要を押し上げています。技術の進歩は、がんバイオマーカーの精度と信頼性を向上させ、最終的に診断精度と治療モニタリングを強化することで、この増加傾向に重要な役割を果たしています。こうした技術革新は患者の予後改善に貢献し、市場の成長をさらに加速させる。

市場概要
オミックス技術
- プロテオミクス
- 免疫測定
- 質量分析
- 2Dゲル電気泳動
- タンパク質マイクロアレイ
- その他のプロテオーム技術
- ゲノミクス
- 次世代シーケンシング
- ポリメラーゼ連鎖反応
- インサイチューハイブリダイゼーション
- その他のオミックス技術
イメージング技術
- 超音波画像診断
- コンピュータ断層撮影
- 磁気共鳴画像
- 陽電子放出断層撮影
- マンモグラフィー

がんバイオマーカー市場：がんタイプ別

非ホジキンリンパ腫
乳がん
肺がん
大腸がん
前立腺がん
悪性黒色腫
白血病
甲状腺がん
膀胱がん
非ホジキンリンパ腫
腎臓がん
その他のがん

がんバイオマーカー市場：製品別

市場概要
機器
- 画像機器
- 病理学に基づく機器
- 生検器具
消耗品
- 抗体
- キットと試薬
- プローブ
バイオインフォマティクスソフトウェア

がんバイオマーカー市場：用途別

市場概要
診断
研究開発
予測
リスクアセスメント
その他の用途

がんバイオマーカー市場：エンドユーザー別

市場概要
診断検査室
バイオ医薬品企業とクロス
研究・学術機関
その他のエンドユーザー

がんバイオマーカー市場：地域別規模

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域

競合情勢

上位5社の比較
主要企業の市場ポジショニング（2023年）
主な市場企業が採用した戦略
市場における最近の活動
主要企業の市場シェア（2023年）

主要企業プロファイル

F. Hoffmann-La Roche Ltd.（Switzerland）
Thermo Fisher Scientific Inc.（US）
Qiagen（Netherlands）
Bio-Rad Laboratories, Inc.（US）
Illumina, Inc.（US）
Agilent Technologies, Inc.（US）
Abbott Laboratories（US）
bioMerieux（France）
Merck KGaA（Germany）
Becton, Dickinson and Company（US）
Myriad Genetics, Inc.（US）
Sysmex Corporation（Japan）
Hologic, Inc.（US）
Quest Diagnostics（US）
Centogene N.V.（Germany）
BioGenex（US）
Siemens Healthineers（Germany）
Exact Sciences（US）
R&D Systems, Inc.（US, part of Bio-Techne）
Biovision Inc.（US）
Olink（Sweden）
Meso Scale Diagnostics, LLC（US）
Invivoscribe, Inc.（US）
INOVIQ Ltd.（Australia）

Product Code: SQMIG35A2775

Global Cancer Biomarkers Market size was valued at USD 23.8 billion in 2022 and is poised to grow from USD 26.47 billion in 2023 to USD 61.88 billion by 2031, growing at a CAGR of 11.8% during the forecast period (2024-2031).

The anticipated growth of the global cancer biomarkers market is closely tied to the rising prevalence of various cancer types, including breast, prostate, and lung cancers. The increasing incidence of these cancers is a key factor driving the market's expansion in the coming years. Moreover, the growing importance of biological and targeted therapies in cancer treatment is boosting the demand for effective biomarkers. Technological advancements play a critical role in this upward trend by improving the accuracy and reliability of cancer biomarkers, ultimately enhancing diagnostic precision and treatment monitoring. These innovations contribute to better patient outcomes, further accelerating the market's growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Biomarkers Market Segmental Analysis

Global Cancer Biomarkers Market is segmented by Profiling Technology, Cancer Type, Product, Application, End User and region. Based on Profiling Technology, the market is segmented into Omics Technologies, Imaging Technologies. Based on Cancer Type, the market is segmented into Non-Hodgkin's Lymphoma, Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Leukemia, Thyroid Cancer, Bladder Cancer, Non-Hodgkin's Lymphoma, Kidney Cancer, and Other Cancers. Based on Product, the market is segmented into Instruments, Bioinformatics Software. Based on Application, the market is segmented into Diagnostics, Research & Development, Prognostics, Risk Assessment, and Other Applications. Based on End User, the market is segmented into Diagnostic Laboratories, Biopharmaceutical Companies and Cros, Research and Academic Institutes, Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Drivers of the Global Cancer Biomarkers Market

Many pharmaceutical companies are actively investing in cutting-edge research and development aimed at creating innovative biomarkers specifically designed for cancer diagnosis and treatment. Several of these biomarkers are approaching the final stages of development and are expected to make a substantial impact once introduced to the market. These upcoming biomarkers have the potential to transform cancer care by offering improved accuracy and effectiveness in both diagnosis and treatment. Their introduction could lead to more personalized approaches, significantly enhancing patient outcomes and setting new standards in the management of cancer.

Restraints in the Global Cancer Biomarkers Market

The increasing global incidence of cancer and the growing need for diagnostic tests highlight a major challenge in the cancer biomarker market: the lack of extensive reimbursement policies for biomarker tests in both emerging and developed countries. This gap in coverage limits the widespread adoption of these essential diagnostic tools, thereby restraining the global demand for biomarkers. Moreover, the high costs associated with cancer diagnosis and treatment, which are particularly burdensome in emerging economies, pose a significant obstacle. These financial constraints further impede the accessibility and use of advanced biomarkers, affecting their market growth and adoption.

Market Trends of the Global Cancer Biomarkers Market

The cancer biomarkers market is set for substantial growth over the next decade, driven by several key factors. A major catalyst is the increasing awareness among patients and healthcare professionals about the crucial role early detection plays in managing cancer. This growing understanding promotes a proactive approach to diagnosis, leading to earlier interventions that can significantly enhance treatment effectiveness. This shift towards early detection is expected to stimulate demand for cancer biomarkers, as timely identification of malignancies can lead to better outcomes and more effective treatments. As awareness continues to rise, the market for these diagnostic tools is likely to expand, reflecting the critical need for advancements in cancer care.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Pricing Analysis
Patent Analysis
Value Chain Analysis
Supply Chain Analysis
Trade Analysis
Technology Analysis
Customer & Buying Criteria Analysis
Case Study Analysis

Cancer Biomarkers Market by Profiling Technology

Market Overview
Omics Technologies
- Proteomics
- Immunoassays
- Mass Spectrometry
- 2D Gel Electrophoresis
- Protein Microarrays
- Other Proteomic Technologies
- Genomics
- Next-Generation Sequencing
- Polymerase Chain Reaction
- In Situ Hybridization
- Other Omics Technologies
Imaging Technologies
- Ultrasound Imaging
- Computed Tomography
- Magnetic Resonance Imaging
- Positron Emission Tomography
- Mammography

Cancer Biomarkers Market by Cancer Type

Non-Hodgkin'S Lymphoma
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Melanoma
Leukemia
Thyroid Cancer
Bladder Cancer
Non-Hodgkin's Lymphoma
Kidney Cancer
Other Cancers

Cancer Biomarkers Market by Product

Market Overview
Instruments
- Imaging Instruments
- Pathology-Based Instruments
- Biopsy Instruments
Consumables
- Antibodies
- Kits & Reagents
- Probes
Bioinformatics Software

Cancer Biomarkers Market by Application

Market Overview
Diagnostics
Research & Development
Prognostics
Risk Assessment
Other Applications

Cancer Biomarkers Market by End User

Market Overview
Diagnostic Laboratories
Biopharmaceutical Companies And Cros
Research And Academic Institutes
Other End Users

Cancer Biomarkers Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Qiagen (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Illumina, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agilent Technologies, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
bioMerieux (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Becton, Dickinson and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Myriad Genetics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sysmex Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hologic, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Quest Diagnostics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Centogene N.V. (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioGenex (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exact Sciences (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
R&D Systems, Inc. (US, part of Bio-Techne)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biovision Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Olink (Sweden)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Meso Scale Diagnostics, LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Invivoscribe, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
INOVIQ Ltd. (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments